Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.58 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900788 | 0.98 | OPRD1 (0.60) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL31243908 | 0.96 | OPRD1 (0.55) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL31243859 | 0.93 | OPRD1 (0.58) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL31243865 | 0.93 | OPRD1 (0.58) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL31243860 | 0.93 | KISS1R (0.52) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL31243925 | 0.93 | TFPI (0.60) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL30900782 | 0.93 | TFPI (0.65) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL30900790 | 0.93 | TFPI (0.65) | OPRD1OPRM1OPRK1OPRL1TFPI | |
| SCHEMBL31243869 | 0.93 | OPRD1 (0.69) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31243857 | 0.93 | OPRD1 (0.67) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |